


# Chemotherapy



S. Karger  
Medical and Scientific Publishers  
Basel · Freiburg · Paris ·  
London · New York ·  
New Delhi · Bangkok · Beijing ·  
Tokyo · Kuala Lumpur ·  
Singapore · Sydney

**KARGER**

*A meeting report of the 2nd international Else Kröner-Fresenius Symposium on Nanomedicine*



# Nanomedicine – Basic and Clinical Applications in Diagnostics and Therapy

**Editor**  
**Christoph Alexiou**

Fields of Interest: Cell Biology; Molecular Biology; Oncology; Otorhinolaryngology

Nanomedicine – the application of nanotechnology to human health – is a promising field of research at the interface of physical, chemical, biological, and medical science. Recent advances have made it possible to analyze biological systems at cellular and subcellular levels, offering numerous promising approaches to improve medical diagnosis and therapy. It is expected that nanomedicine will have a great impact especially on drug delivery and imaging. In this context, the development of targeted, highly specific nanoparticles is of pivotal importance. The results of these advances will offer personalized diagnostic tools and treatments in the future.

Based on the 2nd Else Kröner-Fresenius-Symposium, this book presents a broad spectrum of topics ranging from nanoscale drug delivery/drug design to nanotoxicity and from diagnostics and imaging to therapeutic applications including antibody therapies. The contributions are authored by leading experts in the field and provide an excellent overview of the current knowledge in nanomedicine. Due to the interdisciplinary nature of the subject area this volume will be of special interest to physicians, biologists, chemists, engineers, and physicists as well as to students in the respective fields.

## Contents

Preface: **Pahernik, S.**  
Introduction: **Alexiou, C.**  
Speakers at the Symposium

### Nanoscale Drug Delivery/Drug Design

Nanocarriers for the Delivery of Drugs, Genes, and Diagnostics: **Torchilin, V.P.**  
Synthesis of Magnetic Nanoparticles and Magnetic Fluids for Biomedical Applications: **Vékás, L.; Tombácz, E.; Turcu, R.; Morjan, I.; Avdeev, M.V.; Krasia-Christoforou, T.; Socoliuc, V.**  
Nanotechnology-Based Spatiotemporal Controlled Drug Delivery Strategies: **Biswas, S.; Kumar, C.S.S.R.**

### Nanotoxicity

Preclinical Efficacy and Toxicity Testing of Engineered Nanomaterials: **Grossman, J.H.; McNeil, S.E.**  
Interactions of Carbon Nanotubes with the Immune System: Focus on Mechanisms of Internalization and Biodegradation: **Fadeel, B.; Shvedova, A.A.; Kagan, V.E.**

### Diagnostics and Imaging

Magnetic Particle Imaging: Principles and Clinical Application: **Buzug, T.M.; Sattel, T.F.; Erbe, M.; Biederer, S.; Finas, D.; Diedrich, K.; Vogt, F.; Barkhausen, J.; Borgert, J.; Lütke-Buzug, K.; Knopp, T.**

Nanoparticles in Clinical Trials: **Hedgire, S.; McDermott, S.; Harisinghani, M.**

Medical Applications of Plasmonic Nanoparticles: **Alvarez-Puebla, R.A.; Liz-Marzán, L.M.**  
Pancreatic Cancer Stem Cells as New Targets for Diagnostics and Therapy: **Clausell-Tormos, J.; Heeschen, C.**

### Therapeutic Applications

Nanomedicine Approaches for Cancer Stem Cell Targeting and Personalized Cancer Treatment: **Block, I.; Schmidt, S.; Lund Hansen, P.; Riedel, A.; Christiansen, H.; Mollenhauer, J.**  
Targeted Iron Oxide Nanocomplex as a Theranostic Agent for Cancer: **Chang, E.H.**  
Local Cancer Therapy with Magnetic Nanoparticles: **Tietze, R.; Lyer, S.; Schreiber, E.; Mann, J.; Dürr, S.; Alexiou, C.**  
Parameters Influencing the Efficacy of Magnetic Heating of Small Breast Tumors: **Hilger, I.; Kaiser, W.A.**

### Antibody Therapies

Galectins, Glycans, and Mucins as Targets for Novel and Specific Antibody Therapies in Gynecologic Cancer Therapies: **Jeschke, U.; Wiest, I.R.M.; Schindlbeck, C.; Dian, D.; Friese, K.**  
The Commercial Development of Antibodies as Drugs: **Eaton, M.A.W.; Adair, J.R.**

Author Index / Subject Index

[www.karger.com/ekfsy](http://www.karger.com/ekfsy)

KI 11241

**Else Kröner-Fresenius Symposia, Vol. 2**  
Series Editor: Pahernik, S. (Heidelberg)  
ISSN 1663-0114

**Nanomedicine – Basic and Clinical Applications in Diagnostics and Therapy**

Editor: Alexiou, C. (Erlangen)  
VIII + 202 p., 80 fig., 56 in color, 11 tab., hard cover, 2011  
CHF 79.– / EUR 66.– / USD 93.00  
Prices subject to change  
EUR price for Germany, USD price for USA only  
ISBN 978-3-8055-9818-7  
e-ISBN 978-3-8055-9819-4

Please send: \_\_\_\_\_ copy/ies

Postage and handling free with prepayment

### Payment:

Please charge to my credit card  
 American Express  Diners  Eurocard  
 MasterCard  Visa

Card No.: \_\_\_\_\_

Exp. date: \_\_\_\_\_

CVV/CVC \_\_\_\_\_

(3 digits in the signature field on the back of Visa and MasterCard)

Check enclosed  Please bill me

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Fax: +41 61 306 12 34

S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)  
E-Mail orders@karger.ch, [www.karger.com](http://www.karger.com)

Name/Address: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Date: \_\_\_\_\_

Signature: \_\_\_\_\_

**KARGER**



Paul Ehrlich  
1854–1915

The founder of chemotherapy

# Chemotherapy

**International Journal of Experimental and Clinical Chemotherapy**

Founded 1959 as 'Chemotherapia' by H.P. Kuemmerle and P. Rentchnick  
Continued by H. Schönfeld (1968–2001)

---

## Editor-in-Chief

F. Sörgel, Nürnberg-Heroldsberg

---

## Editorial Board

C. Chiesa, Rome  
M. Grace, Pennington, N.J.  
S. Horkovics-Kovats, Kundl  
S. Kohno, Nagasaki  
C. Landersdorfer, Melbourne, Vic.  
R.C. Moellering Jr., Boston, Mass.  
K.G. Naber, Straubing

R. Nau, Göttingen  
D. Nix, Tucson, Ariz.  
P. Preziosi, Rome  
A. Reiter, Mannheim  
A. Schmidt, Düsseldorf  
F. Van Bambeke, Brussels  
N. White, Bangkok

---

**KARGER**

Printed in Switzerland  
on acid-free and non-aging  
paper (ISO 9706) by  
Reinhardt Druck, Basel

Appears bimonthly:  
1 volume per year  
(6 issues)

**Submission**

Only original papers written in English are considered for publication. **Manuscripts should be submitted to 'Chemotherapy' online.** For specific instructions on how to prepare a manuscript for submission, you are encouraged to view the guidelines at [www.karger.com/che](http://www.karger.com/che), where you will also find a link to the **Submission Website**. Names, postal and e-mail addresses of four experts in the appropriate area of research should accompany each manuscript. Selected scientist(s) will be invited to act as referee(s). Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject. Should you have any problems with your submission, please contact:

Prof. F. Sörgel  
S. Karger AG  
Editorial Office 'Chemotherapy'  
P.O. Box  
CH-4009 Basel (Switzerland)  
Tel. +41 61 306 1361  
Fax +41 61 306 1434  
E-Mail [che@karger.ch](mailto:che@karger.ch)

Mailing address for courier deliveries only:

Allschwilerstr. 10  
CH-4055 Basel (Switzerland)

**Conditions**

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Chemotherapy' and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

**Arrangement**

**Title page:** The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

**Full address:** The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

**Key words:** Please supply 3–10 key words in English that reflect the content of the paper.

**Abstract:** Each paper needs an abstract of up to 150 words structured with subheadings as follows: **Background, Methods, Results, Conclusion(s)**.

**Footnotes:** Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

**Tables and illustrations:** Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. For the re-

production of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1200 dpi.

**Color illustrations**

**Online edition:** Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

**Print edition:** Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

**References:** In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as 'unpublished data' and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals ([www.icmje.org](http://www.icmje.org)).

**Examples**

(a) *Papers published in periodicals:* Sun J, Koto H, Chung KF: Interaction of ozone and allergen challenges on bronchial responsiveness and inflammation in sensitised guinea pigs. *Int Arch Allergy Immunol* 1997;112:191–195.

(b) *Papers published only with DOI numbers:* Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. *Int Arch Allergy Immunol* DOI: 10.1159/000063858.

(c) *Monographs:* Matthews DE, Farewell VT: *Using and Understanding Medical Statistics*, ed 3, revised. Basel, Karger, 1996.

(d) *Edited books:* Parren PW, Burton DR: Antibodies against HIV-1 from phage display libraries: Mapping of an immune response and progress towards antiviral immunotherapy; in Capra JD (ed): *Antibody Engineering*. Chem Immunol. Basel, Karger, 1997, vol 65, pp 18–56.

**Reference Management Software:** Use of EndNote is recommended for easy management and formatting of citations and reference lists.

**Digital Object Identifier (DOI)**

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at [www.doi.org](http://www.doi.org).

**Supplementary Material**

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supple-

mentary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

**Author's Choice™**

Karger's Author's Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at [www.karger.com](http://www.karger.com). The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at [www.karger.com/authors\\_choice](http://www.karger.com/authors_choice).

**NIH-Funded Research**

The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author's Choice™ service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy is available at <http://publicaccess.nih.gov/FAQ.htm#a1>

**Self-Archiving**

Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

**Page Charges**

There is no page charge for papers of 4 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 12 manuscript pages (including tables, illustrations and references).

**Proofs**

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer's errors, are charged to the author.

**Reprints**

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

**Photo on title page**

Courtesy of the Paul-Ehrlich-Institut, Langen, Germany

**ISSN Print Edition:** 0009-3157  
**ISSN Online Edition:** 1421-9794

**Journal Homepage:** [www.karger.com/che](http://www.karger.com/che)

**Publication Data:** 'Chemotherapy' is published 6 times a year. Volume 57 with 6 issues appears in 2011.

**Copyright:** © 2011 S. Karger AG, Basel (Switzerland). All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.

**Disclaimer:** The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

**Subscription Rates:** Subscriptions run for a full calendar year. Prices are given per year.

*Personal subscription:*

Print or Online	Print+Online combined
CHF 1066.–	CHF 1114.–
EUR 789.50	EUR 825.50
USD 993.50	USD 1041.50

**postage and handling** (added to print and print+online)  
 CHF 39.30 Europe, CHF 58.50 Overseas  
 EUR 29.40  
 USD 54.60

*Institutional subscription:*

Print or Online	Print+Online combined
CHF 2132.–	CHF 2345.–
EUR 1579.–	EUR 1737.–
USD 1993.00	USD 2192.00

**postage and handling** (added to print and print+online)  
 CHF 49.20 Europe, CHF 73.20 Overseas  
 EUR 36.60  
 USD 68.40

*Airmail surcharge:* CHF 49.80 / USD 46.80

**Back Volumes and Single Issues:** Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at [service@karger.ch](mailto:service@karger.ch).

**Bibliographic Indices:** This journal is regularly listed in bibliographic services, including *Current Contents®* and PubMed/MEDLINE.

**Photocopying:** This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for the personal or internal use of specific clients, provided that the stated fee is paid per copy directly to

Copyright Clearance Center Inc.  
 222 Rosewood Drive  
 Danvers, MA 01923 (USA)

A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box CH-4009 Basel (Switzerland).

**Subscription Orders:**

Orders can be placed at agencies, bookstores, directly with the Publisher

**S. Karger AG**

Medical and Scientific Publishers  
 P.O. Box  
 CH-4009 Basel  
 Switzerland  
 (for courier services only:  
 Allschwilerstrasse 10  
 CH-4055 Basel)  
 t: +41 61 306 11 11  
 f: +41 61 306 12 34  
 e: [karger@karger.ch](mailto:karger@karger.ch)  
 w: [www.karger.com](http://www.karger.com)

or further Karger offices or representatives:

Germany  
**S. Karger GmbH**  
 Postfach  
 79095 Freiburg  
 Deutschland  
 (Hausadresse: Wilhelmstrasse 20A,  
 79098 Freiburg)  
 t: +49 761 45 20 70  
 f: +49 761 45 20 714  
 e: [information@karger.de](mailto:information@karger.de)  
 w: [www.karger.de](http://www.karger.de)

Japan  
**Karger Japan, Inc.**  
 Shiba Daimon Asahi Bldg. 2F  
 1-2-23 Shiba Daimon  
 Minato-ku  
 Tokyo 105-0012  
 Japan  
 t: +81 3 6435 6242  
 f: +81 3 6435 6244  
 e: [publisher@karger.jp](mailto:publisher@karger.jp)  
 w: [www.karger.jp](http://www.karger.jp)

USA  
**S. Karger Publishers, Inc.**  
 26 West Avon Road  
 P.O. Box 529  
 Unionville, CT 06085  
 USA  
 Toll free: +1 800 828 5479  
 t: +1 860 675 7834  
 f: +1 860 675 7302  
 e: [karger@snet.net](mailto:karger@snet.net)

France  
**Librairie Médi-Sciences Sarl**  
 36, bd de Latour-Maubourg  
 75007 Paris  
 France  
 t: +33 (0) 1 45 51 42 58  
 f: +33 (0) 1 45 56 07 80  
 e: [librairie@medi-sciences.fr](mailto:librairie@medi-sciences.fr)  
 w: [www.medi-sciences.fr](http://www.medi-sciences.fr)

Gulf Council Countries, Iran,  
 Middle East, North Africa, Turkey  
**Trans Middle East International  
 Distribution Co. Ltd.  
 KaSha**  
 134 Queen Rania Al Abdullah Street  
 Jordan Trade Center Bldg. 3rd Floor  
 P.O. Box 2376  
 Amman 11953  
 Jordan  
 t: +962 6 515 3467  
 f: +962 6 515 3472  
 e: [info@kasha.com](mailto:info@kasha.com)  
 w: [www.KaShaonline.com](http://www.KaShaonline.com)

South East Asia, China and Taiwan  
**Karger Regional Office (Malaysia)**  
 CEO Suite Kuala Lumpur  
 Quill 7, 27th Floor  
 Jalan Stesen Sentral 5  
 KL Sentral  
 Kuala Lumpur 50470  
 Malaysia  
 t: +60 3 2776 6803  
 f: +60 3 2776 6999  
 e: [service@karger.cn](mailto:service@karger.cn); [r.chew@karger.cn](mailto:r.chew@karger.cn)

**Karger China**  
 10th Floor, Twin Towers (East)  
 B12 Jianguomenwai Avenue  
 Beijing 100022  
 China  
 t: +86 10 5123 5033  
 f: +86 10 5123 5122  
 e: [service@karger.cn](mailto:service@karger.cn); [r.chew@karger.cn](mailto:r.chew@karger.cn)  
 w: [www.karger.com](http://www.karger.com)

India, Bangladesh, Sri Lanka  
**Medscience India**  
 Plot No. 17, Yusuf Sarai Market  
 B.L. Glass Building, 2nd Floor  
 Sri Aurobindo Marg  
 New Delhi 110 016  
 India  
 t: +91 11 46029 633  
 f: +91 11 46029 634  
 c: +91 98 91052 128  
 e: [medsci.india@gmail.com](mailto:medsci.india@gmail.com)

**Change of Address:**

Both old and new address should be sent to the subscription source.

# 15th International Congress on Infectious Diseases

BANGKOK, THAILAND • JUNE 13~16, 2012



Organized by the International Society for Infectious Diseases



In collaboration with the Infectious Disease Association of Thailand

**For further information please contact:**  
**Email: [info@isid.org](mailto:info@isid.org) Web: <http://www.isid.org>**

---

# Contents

[See the journal website for contents](#)



# CHEP

## 2<sup>ND</sup> WORLD CONGRESS ON **CONTROVERSIES IN THE MANAGEMENT OF VIRAL HEPATITIS**




BERLIN, GERMANY • OCTOBER 18-20, 2012

### CO-CHAIRPERSONS

**Jürgen Rockstroh, MD**  
Germany


**Jonathan M. Schapiro, MD**  
Israel



[www.comtecmed.com/chep](http://www.comtecmed.com/chep) • [chep@comtecmed.com](mailto:chep@comtecmed.com)



*An essential manual for beginners and senior researchers alike*



# Guide for Investigator Initiated Trials

**Editor**  
**Gerhard Fortwengel**

**In collaboration with:**  
Isabel Böckler, Rafael Dymek, Sebastian Häckl,  
Alexander Hahn, Katrin Hertwig, Cynthia Kuhn,  
Birgit Lindner, Sarah Lütken, Christoph Neumann,  
Marcus Paul, Madlen Pomp, Nadja Schachteli

Documentation, Communication, General Medicine,  
Data Processing, Medical Law

For academic medical faculty unfamiliar with national and international regulations, the prospect of initiating and managing a clinical trial can be intimidating. The development of protocols and case report forms, compliance with regulatory requirements, the monitoring of clinical trials as well as the responsibilities of documentation are just some of the tasks the sponsor-investigator is faced with. This book covers the entire spectrum of a clinical trial, reviewing the different stages step by step: financial planning, crucial aspects of trial design, the authorization process and, finally, documentation. Moreover, it contains helpful tips, a practical glossary, instructions and a large number of resources related to the relevant regulations and forms conforming to the 'International Conference on Harmonization and Good Clinical Practice' and the European legislation. This makes the publication at hand an essential 'cookbook' for both academic faculty new to clinical trials as well as seasoned sponsors-investigators.

## Contents

- Risk-Benefit Analysis
- Study Types and Study Design
- Investigational Medicinal Products
- Study Protocol
- Case Report Forms
- Financing
- Qualifications, CVs of Site Staff, Training, Delegation of Authority
- EudraCT
- Contracts
- Informed Consent
- Investigator's Brochure/Summary of Product Characteristics
- Insurance
- Health Authority Approval
- Ethics
- Trial Master File, Updating and Archiving
- Documentation
- Data Management
- Screening
- Pharmacovigilance
- Patient Compliance
- Source Data Verification
- Quality
- Monitoring
- Biometry
- Multicentre Trials
- Final Study Report and Publication
- Appendix 1: Common Abbreviations
- Appendix 2: Glossary
- Appendix 3: Health Authority Addresses in the European Area

[www.karger.com/documentation](http://www.karger.com/documentation)

### Guide for Investigator Initiated Trials

Editor: Fortwengel, G. (Hannover)  
VI + 148 p., 7 fig., spiral bound, 2011  
CHF 49.- / EUR 41.- / USD 58.00  
Prices subject to change  
EUR price for Germany, USD price for USA only  
ISBN 978-3-8055-9684-8  
e-ISBN 978-3-8055-9685-5

Please send: \_\_\_\_\_ copy/ies

Postage and handling free with prepayment

**O  
r  
d  
e  
r  
F  
o  
r  
M  
a  
i  
l**

#### Payment:

- Please charge to my credit card  
 American Express     Diners     Eurocard  
 MasterCard     Visa

Card No.: \_\_\_\_\_

Exp. date: \_\_\_\_\_

CVV/CVC \_\_\_\_\_

(3 digits in the signature field on the back of Visa and MasterCard)

- Check enclosed     Please bill me

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Fax: +41 61 306 12 34

S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)  
E-Mail orders@karger.ch, [www.karger.com](http://www.karger.com)

Name/Address:

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Date:

Signature:

**KARGER**

Impact Factor in 2010: 2.648

# Journal of Molecular Microbiology and Biotechnology

Editor-in-Chief

**M.H. Saier, Jr.**, La Jolla, Calif.

Senior Editors

**M.H. Brown**, Adelaide  
**J. Deutscher**, Thiverval-Grignon  
**G. Gosset**, Cuernavaca  
**M. Inouye**, Piscataway, N.J.  
**M. Müller**, Freiburg  
**D.H. Nies**, Halle/Saale

**I. Paulsen**, Sydney  
**R. Rabus**, Oldenburg  
**F.X. Soberon**, Cuernavaca  
**J. Stülke**, Göttingen



We are entering a new and exciting era of microbiological study and application. Recent advances in the now established disciplines of genomics, proteomics and bioinformatics, together with extensive cooperation between academic and industrial concerns have brought about an integration of basic and applied microbiology as never before. The *Journal of Molecular Microbiology and Biotechnology* (JMMB) aims to reflect this development by publishing original research papers from all areas of microbiology and biotechnology. It also features written symposia on selected topics, timely reviews, minireviews, and a section devoted to correspondence and comments. Theoretical approaches and descriptions of novel, microbiologically relevant software will also be considered. Contributions and ideas from large segments of the scientific community are welcome to make JMMB a viable, much-needed and up-and-coming forum for current basic and applied microbiological research.

#### Selected contributions

Role of CcpA in Polyhydroxybutyrate Biosynthesis in a Newly Isolated *Bacillus* sp. MA3.3: **Lopes, M.S.L.** (São Paulo); **Steinert, N.** (Erlangen); **Rojas, J.D.** (São Paulo); **Hillen, W.** (Erlangen); **Gomez, J.G.C.**; **Silva, L.F.** (São Paulo)

Evolution of Patchily Distributed Proteins Shared between Eukaryotes and Prokaryotes: *Dictyostelium* as a Case Study: **Andersson, J.O.** (Uppsala)

Genome-Wide Gene Expression Analysis of the Switch between Acidogenesis and Solventogenesis in Continuous Cultures of *Clostridium acetobutylicum*: **Grimmler, C.** (Göttingen); **Janssen, H.** (Rostock); **Krauß, D.** (Freising); **Fischer, R.-J.**; **Bahl, H.** (Rostock); **Dürre, P.** (Ulm); **Liebl, W.** (Freising); **Ehrenreich, A.** (Göttingen/Freising)

Oxygen-Sensitive Global Regulator, Anr, Is Involved in the Biosynthesis of Poly(3-Hydroxybutyrate) in *Pseudomonas extremaustralis*: **Tribelli, P.M.**; **Méndez, B.S.**; **López, N.I.** (Buenos Aires)

Membrane Topology Analysis of the *Escherichia coli* Aromatic Amino Acid Efflux Protein YddG: **Airich, L.G.**; **Tsyrzhenpova, I.S.**; **Vorontsova, O.V.**; **Feofanov, A.V.**; **Doroshenko, V.G.**; **Mashko, S.V.** (Moscow)

Effect of Probiotic-Fermented Milk Administration on Gastrointestinal Survival of *Lactobacillus casei* ATCC 393 and Modulation of Intestinal Microbial Flora: **Sidira, M.**; **Galanis, A.**; **Ypsilantis, P.**; **Karapetsas, A.**; **Progaki, Z.**; **Simopoulos, C.**; **Kourkoutas, Y.** (Alexandroupolis)

Interactions between Glycolytic Enzymes of *Mycoplasma pneumoniae*: **Dutow, P.**; **Schmidl, S.R.**; **Ridderbusch, M.**; **Stülke, J.** (Göttingen)

Construction of a New Sensitive Molecular Tool for the Study of Gene Expression in *Enterococcus faecalis*: **Le Jeune, A.**; **Touchet, F.**; **Zhao, C.**; **Hartke, A.**; **Auffray, Y.**; **Benachour, A.** (Caen)

More information at

[www.karger.com/mmb](http://www.karger.com/mmb)

- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation



**Journal of Molecular Microbiology and Biotechnology**

2012: Volumes 22

6 issues per volume

Language: English

ISSN 1464-1801 (print)

ISSN 1660-2412 (online)

Listed in bibliographic services, including MEDLINE, Biological Abstracts, Science Citation Index Expanded, Biotechnology Citation Index, EMBASE/Excerpta Medica

# Chemotherapy

## Pharmacology

**449 Anticancer Effects of Imperatorin Isolated from *Angelica dahurica*: Induction of Apoptosis in HepG2 Cells through both Death-Receptor- and Mitochondria-Mediated Pathways**

Luo, K.; Sun, J. (Hangzhou); Chan, J.Y.-W. (Hangzhou/Hong Kong); Yang, L.; Wu, S. (Hangzhou); Fung, K.-P. (Hangzhou/Hong Kong); Liu, F. (Hangzhou)

## Microbiology

**505 In vitro Activities of the Novel Ceragenin CSA-13, Alone or in Combination with Colistin, Tobramycin, and Ciprofloxacin, against *Pseudomonas aeruginosa* Strains Isolated from Cystic Fibrosis Patients**

Bozkurt-Guzel, C. (Istanbul); Savage, P.B. (Provo, Utah); Gerceker, A.A. (Istanbul)

**511 In vitro Activities of Nisin Alone or in Combination with Vancomycin and Ciprofloxacin against Methicillin-Resistant and Methicillin-Susceptible *Staphylococcus aureus* Strains**

Dosler, S.; Gerceker, A.A. (Istanbul)

## Experimental Chemotherapy

**460 Antitumor Activity from the Combined Application of Poly(I:C) and Chemotherapeutics in Human Metastatic Pharyngeal Cell Lines**

Matijević, T.; Kirinec, G.; Pavelić, J. (Zagreb)

**488 Bmi-1 Promotes the Chemoresistance, Invasion and Tumorigenesis of Pancreatic Cancer Cells**

Yin, T.; Wei, H.; Leng, Z.; Yang, Z.; Gou, S.; Wu, H.; Zhao, G.; Hu, X.; Wang, C. (Wuhan)

## Clinical Study

**497 Risk Factors for Gametocyte Carriage in Uncomplicated Falciparum Malaria in Children before and after Artemisinin-Based Combination Treatments**

Sowunmi, A.; Okuboyejo, T.M.; Gbotosho, G.O.; Happi, C.T. (Ibadan)

## Review

**468 Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer**

Shamseddine, A.I. (Beirut); Farhat, F.S. (Saida)

**517 Acknowledgement to the Reviewers**

after **520 Contents Vol. 57, 2011**